Praluzatamab ravtansine  (Synonyms: CX-2009; CD166)

Praluzatamab ravtansine (CX-2009) is an anti-CD166 antibody drug conjugate (ADC) with an K_d value of 25.15 nM. Praluzatamab ravtansine contains an anti-CD166 monoclonal antibody Praluzatamab (HY-P99788) conjugated to the microtubule inhibitor DM4 (HY-12454). Praluzatamab ravtansine shows tumor targeting and can be used for the study of lung cancer and breast cancer^[1][2].

CD166^[1]

Praluzatamab ravtansine (110 µg; i.v.; single dose) has tumor targeting in CD166 positive H292 tumor-bearing nude mice^[2].
Praluzatamab ravtansine (110 µg and 510 µg; i.v.; single dose) is activated in tumor tissue of H292 xenotransplantation mice^[2].
Praluzatamab ravtansine (5 mg/kg; i.v.; single dose on day 0 and 7) significantly reduces tumor volume in H292 xenograft tumor-bearing mice model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2145115-85-9

[Praluzatamab ravtansine]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Boni V, et al. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 May 13;28(10):2020-2029.  [Content Brief]

  [2]. Chomet M, et al. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice. Theranostics. 2020 Apr 27;10(13):5815-5828.  [Content Brief]